Bioceres price target lowered to $6.50 from $7 at Canaccord

Canaccord analyst Austin Moeller lowered the firm’s price target on Bioceres (BIOX) to $6.50 from $7 and keeps a Buy rating on the shares. The firm noted management announced its intent to pivot away from Bioceres’ seed business to focus on trait development and leverage key partnerships to expand its footprint internationally.